Complete financial analysis of Codexis, Inc. (CDXS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Codexis, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nitin Fire Protection Industries Limited (NITINFIRE.NS) Income Statement Analysis – Financial Results
- Nitta Corporation (5186.T) Income Statement Analysis – Financial Results
- Andritz AG (ADRZF) Income Statement Analysis – Financial Results
- Alpine Banks of Colorado (ALPIB) Income Statement Analysis – Financial Results
- Reply S.p.A. (REY.MI) Income Statement Analysis – Financial Results
Codexis, Inc. (CDXS)
About Codexis, Inc.
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.14M | 138.59M | 104.75M | 69.06M | 68.46M | 60.59M | 50.02M | 48.84M | 41.80M | 35.31M | 31.92M | 88.30M | 123.87M | 107.10M | 82.91M | 50.48M | 25.33M | 12.13M |
| Cost of Revenue | 12.81M | 38.03M | 22.21M | 13.74M | 15.63M | 12.62M | 14.33M | 9.75M | 6.59M | 9.73M | 14.55M | 30.65M | 41.78M | 27.98M | 16.68M | 13.19M | 8.32M | 1.81M |
| Gross Profit | 57.33M | 100.56M | 82.55M | 55.31M | 52.83M | 47.97M | 35.70M | 39.08M | 35.22M | 25.58M | 17.37M | 57.65M | 82.08M | 79.12M | 66.23M | 37.29M | 17.01M | 10.32M |
| Gross Profit Ratio | 81.74% | 72.56% | 78.80% | 80.10% | 77.17% | 79.17% | 71.36% | 80.03% | 84.25% | 72.45% | 54.41% | 65.29% | 66.27% | 73.87% | 79.88% | 73.87% | 67.16% | 85.11% |
| Research & Development | 58.89M | 80.10M | 55.92M | 44.19M | 33.87M | 29.98M | 29.66M | 22.23M | 20.67M | 22.76M | 31.61M | 56.79M | 61.05M | 52.41M | 54.73M | 45.55M | 35.64M | 17.26M |
| General & Administrative | 52.95M | 51.87M | 49.02M | 34.75M | 31.00M | 28.79M | 28.31M | 24.92M | 22.02M | 21.64M | 26.41M | 30.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 300.00K | 300.00K | 300.00K | 300.00K | 500.00K | 500.00K | 700.00K | 500.00K | 300.00K | 300.00K | 500.00K | 400.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 53.25M | 52.17M | 49.32M | 35.05M | 31.50M | 29.29M | 29.01M | 25.42M | 22.32M | 21.94M | 26.91M | 31.38M | 36.94M | 33.84M | 29.87M | 35.71M | 19.71M | 11.88M |
| Other Expenses | 13.27M | 124.00K | 1.15M | -156.00K | -656.00K | -291.00K | -92.00K | -94.00K | -168.00K | -234.00K | 24.74M | -326.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 125.40M | 132.27M | 105.24M | 79.23M | 65.38M | 59.27M | 58.67M | 47.65M | 42.99M | 44.69M | 58.51M | 88.16M | 97.99M | 86.25M | 84.60M | 81.26M | 55.36M | 29.14M |
| Cost & Expenses | 138.21M | 170.30M | 127.45M | 92.98M | 81.01M | 71.89M | 72.99M | 57.40M | 49.57M | 54.42M | 73.07M | 118.81M | 139.77M | 114.23M | 101.27M | 94.45M | 63.68M | 30.94M |
| Interest Income | 4.17M | 1.44M | 459.00K | 405.00K | 1.29M | 671.00K | 147.00K | 60.00K | 19.00K | 18.00K | 60.00K | 252.00K | 273.00K | 166.00K | 180.00K | 1.54M | 1.49M | 742.00K |
| Interest Expense | 0.00 | 1.44M | 0.00 | 0.00 | 0.00 | 671.00K | 147.00K | 60.00K | 19.00K | 18.00K | 304.00K | 274.00K | 675.00K | 1.20M | 2.04M | 2.37M | 2.53M | 724.00K |
| Depreciation & Amortization | 9.92M | 10.25M | 5.95M | 4.55M | 4.77M | 1.15M | 1.04M | 4.55M | 5.41M | 6.69M | 10.32M | 12.42M | 11.47M | 8.31M | 6.13M | 4.56M | 2.88M | 2.39M |
| EBITDA | -49.28M | -23.07M | -16.75M | -19.37M | -7.99M | -10.15M | -21.93M | -4.02M | -2.36M | -12.64M | -31.07M | -18.17M | -4.84M | 681.00K | -12.06M | -37.87M | -35.67M | -15.69M |
| EBITDA Ratio | -70.26% | -20.60% | -21.67% | -34.64% | -18.33% | -18.64% | -45.92% | -17.54% | -18.59% | -54.13% | -128.71% | -34.56% | -3.36% | 1.26% | -14.54% | -75.03% | -134.09% | -129.36% |
| Operating Income | -68.07M | -31.71M | -22.70M | -23.92M | -12.55M | -11.30M | -22.97M | -8.56M | -7.77M | -19.11M | -41.15M | -30.51M | -15.91M | -7.12M | -18.37M | -43.97M | -38.34M | -18.82M |
| Operating Income Ratio | -97.04% | -22.88% | -21.67% | -34.64% | -18.33% | -18.64% | -45.92% | -17.54% | -18.59% | -54.13% | -128.90% | -34.56% | -12.84% | -6.65% | -22.15% | -87.11% | -151.36% | -155.16% |
| Total Other Income/Expenses | -8.10M | 1.57M | 1.61M | 249.00K | 631.00K | 380.00K | 55.00K | -34.00K | -149.00K | -216.00K | -244.00K | -74.00K | -402.00K | -1.03M | -1.86M | -827.00K | -1.04M | 18.00K |
| Income Before Tax | -76.17M | -33.32M | -21.09M | -23.67M | -11.92M | -10.92M | -22.92M | -8.60M | -7.92M | -19.33M | -41.39M | -30.59M | -16.31M | -8.16M | -20.22M | -44.80M | -39.39M | -18.80M |
| Income Before Tax Ratio | -108.59% | -24.04% | -20.13% | -34.28% | -17.41% | -18.01% | -45.81% | -17.61% | -18.94% | -54.74% | -129.66% | -34.64% | -13.17% | -7.62% | -24.39% | -88.75% | -155.47% | -155.01% |
| Income Tax Expense | 69.00K | 276.00K | 189.00K | 339.00K | 17.00K | -37.00K | 81.00K | -40.00K | -338.00K | -256.00K | -87.00K | 270.00K | 241.00K | 384.00K | 66.00K | 327.00K | -408.00K | -127.00K |
| Net Income | -76.24M | -33.59M | -21.28M | -24.01M | -11.94M | -10.88M | -23.00M | -8.56M | -7.58M | -19.07M | -41.30M | -30.86M | -16.55M | -8.54M | -20.29M | -45.13M | -38.98M | -18.67M |
| Net Income Ratio | -108.69% | -24.24% | -20.31% | -34.77% | -17.43% | -17.95% | -45.97% | -17.52% | -18.13% | -54.01% | -129.39% | -34.95% | -13.36% | -7.97% | -24.47% | -89.40% | -153.86% | -153.96% |
| EPS | -1.12 | -0.51 | -0.33 | -0.40 | -0.21 | -0.21 | -0.50 | -0.21 | -0.19 | -0.50 | -1.08 | -0.84 | -0.46 | -0.35 | -7.74 | -16.63 | -14.36 | -6.88 |
| EPS Diluted | -1.12 | -0.51 | -0.33 | -0.40 | -0.21 | -0.21 | -0.50 | -0.21 | -0.19 | -0.50 | -1.08 | -0.84 | -0.46 | -0.35 | -7.74 | -16.63 | -14.36 | -6.88 |
| Weighted Avg Shares Out | 68.13M | 65.34M | 64.57M | 59.36M | 56.53M | 52.21M | 46.23M | 40.63M | 39.44M | 38.21M | 38.23M | 36.77M | 35.67M | 24.59M | 2.62M | 2.71M | 2.71M | 2.71M |
| Weighted Avg Shares Out (Dil) | 68.13M | 65.34M | 64.57M | 59.36M | 56.53M | 52.21M | 46.23M | 40.63M | 39.44M | 38.21M | 38.23M | 36.77M | 35.67M | 24.59M | 2.62M | 2.71M | 2.71M | 2.71M |
Codexis Documentary Showcases its Specialized Capabilities Engineering High Performance Enzymes to Enable Delivery of Novel Therapeutics
New Film Highlights Company Commitment to Transforming RNAi Therapeutics Landscape New Film Highlights Company Commitment to Transforming RNAi Therapeutics Landscape
Codexis Announces Enhanced Strategic Focus and Extends Projected Cash Runway to Mid-2026
Organization Streamlined to Focus on Continued Advancement and Commercialization of ECO Synthesis™ Platform for RNAi Therapeutics Production
Time to Evolve: 3 Synthetic Biology Stocks to Sell Off Now
The synthetic biology boom of the pandemic era has become a synthetic biology bust. Many synthetic biology stocks promised the moon and delivered mud.
Codexis to Report First Quarter 2023 Financial Results on May 4
REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the...
Codexis, Inc. (CDXS) Q4 2022 Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Stephen Dilly - President, CEO & Director Kevin Norrett - COO Sriram Ryali - CFO Conference Call Participants Steven Mah - Cowen Company...
Codexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of 17.39% and 4.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Codexis to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 23
REDWOOD CITY, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2022 on Thursday, February 23, 2023,...
Codexis, Inc. (CDXS) Q3 2022 Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Brendan Strong - Argot Partners Dr. Stephen Dilly - President and Chief Executive Officer Kevin Norrett - Chief Operating Officer Ross Taylor -...
Codexis (CDXS) Reports Q3 Loss, Tops Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of 16.67% and 9.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Codexis to Report Third Quarter 2022 Financial Results on November 3
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will report its financial results for the third quarter of 2022 on...
Source: https://incomestatements.info
Category: Stock Reports